I used to think the same but given the specificity issues they...

I used to think the same but given the specificity issues they had last year I think they should either just forget about this for now or totally outsource development to keep costs low.
Better off focusing on asthma acquisitions, which i'm sure is the reason the new shareholders bought in. Depending on the nature of the acquisition/announcement, the market cap could double, triple or quadruple in one day. And depending on the mixture of shares issued/cash paid for any acquisition, the share price may do something similar.